Successful, we will reply to you quickly.


Please select the quantity.


Your message is being sent, please wait.




Send mail failed, please send again!


Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway



(PSI7976; PSI 7976)


PSI-7976 Chemical Structure

PSI-7976, the isomer of PSI-7977(HY-15005), is an inhibitor of HCV RNA replication in the HCV replicon assay (EC50=1.07 uM).

Size Price Stock Quantity
10 mM * 1 mL in DMSO $2912 In-stock
1 mg $500 In-stock
5 mg Get quote
10 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL in DMSO €2854 In-stock
1 mg €490 In-stock
5 mg Get quote
10 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: PSI-7976
Cat. No.: HY-15005A

PSI-7976 Data Sheet

  • View current batch:

    Purity: 98.19%

  • Network Version


    Pdf Version Network Version


    Pdf Version


Related Compound Libraries

Biological Activity of PSI-7976

PSI-7976, the isomer of PSI-7977(HY-15005), is an inhibitor of HCV RNA replication in the HCV replicon assay (EC50=1.07 uM).
IC50 value: 1.07 uM (inhibit HCV RNA replication in clone A replicon cells) [1]
Target: HCV; HCV NS5B RNA polymerase
PSI-7851 contains a chiral phosphorous atom and therefore is a mixture of two diastereomers, PSI-7976 and PSI-7977. Both isomers form a common nonisomeric intermediate (PSI-352707) once the carboxyl ester is hydrolyzed. Therefore, the difference in the anti-HCV activity between the two isomers could be due to differences in the kinetics or the substrate specificity of the enzymes responsible for the first hydrolytic step. The ability of PSI-7976, PSI-7977, or PSI-7851 to inhibit HCV RNA replication in clone A replicon cells was measured. Results of this in vitro assay showed that PSI-7977 was a more potent inhibitor of HCV RNA replication than PSI-7976; the isomeric mixture, PSI-7851, demonstrated intermediate activity.
When CatA was incubated with PSI-7977 or PSI-7976 for 150 min, ~18-fold more PSI-352707 was formed when PSI-7977 was the substrate compared with PSI-7976. Moreover, the catalytic efficiency for PSI-7977 with CatA was ~30-fold higher than that for PSI-7976. CatA preferred PSI-7977 as a substrate over PSI-7976 [1].

Protocol (Extracted from published papers and Only for reference)


Chemical Information

M.Wt 529.45 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C₂₂H₂₉FN₃O₉P
CAS No 1190308-01-0
Solvent & Solubility

10 mM in DMSO

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 1.8888 mL 9.4438 mL 18.8875 mL
5 mM 0.3778 mL 1.8888 mL 3.7775 mL
10 mM 0.1889 mL 0.9444 mL 1.8888 mL

References on PSI-7976

[1]. Murakami E, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47.
A phosphoramidate prodrug of 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-monophosphate, PSI-7851, demonstrates potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo. PSI-7851 is a mixture of two diastereoisomers, PSI-7976 and PSI-7977, with PSI-7977 being the more active inhibitor of HCV RNA replication in the HCV replicon assay. To inhibit the HCV NS5B RNA-dependent RNA polymerase, PSI-7851 must be metabolized to the active triphosphate form. The first step, hydrolysis of the carboxyl ester by human cathepsin A (CatA) and/or carboxylesterase 1 (CES1), is a stereospecific reaction. Western blot analysis showed that CatA and CES1 are both expressed in primary human hepatocytes. However, expression of CES1 is undetectable in clone A replicon cells. Studies with inhibitors of CatA and/or CES1 indicated that CatA is primarily responsible for hydrolysis of the carboxyl ester in clone A cells, although in primary human hepatocytes, both CatA and CES1 contribute to the hydrolysis. Hydrolysis of the ester is followed by a putative nucleophilic attack on the phosphorus by the carboxyl group resulting in the spontaneous elimination of phenol and the production of an alaninyl phosphate metabolite, PSI-352707, which is common to both isomers. The removal of the amino acid moiety of PSI-352707 is catalyzed by histidine triad nucleotide-binding protein 1 (Hint1) to give the 5'-monophosphate form, PSI-7411. siRNA-mediated Hint1 knockdown studies further indicate that Hint1 is, at least in part, responsible for converting PSI-352707 to PSI-7411. PSI-7411 is then consecutively phosphorylated to the diphosphate, PSI-7410, and to the active triphosphate metabolite, PSI-7409, by UMP-CMP kinase and nucleoside diphosphate kinase, respectively.

Other Forms

Inhibitor Kit

Related HCV Products

  • ABT-333

    ABT-333 is an NS5B non-nucleoside polymerase inhibitor.

  • Anguizole

    Anguizole is a small molecule inhibitor of HCV replication and alters NS4B(acute)s subcellular distribution.

  • Artemisinin

    Artemisinin (NSC 369397), a widely used anti-malarial drug, is an inhibitor of HCV subgenomic replicon replication.

  • Asunaprevir

    Asunaprevir (BMS-650032) is a potent hepatitis C virus (HCV) NS3 protease inhibitor.

  • Balapiravir

    Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479).

  • Beclabuvir

    Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM.

  • Boceprevir

    Boceprevir(EBP-520, SCH503034) is an HCV protease inhibitor (Ki=14 nM) for the treatment of hepatitis C virus infection.

  • Elbasvir

    Elbasvir (MK-8742) is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.

  • KIN1408

    KIN1408 is an antiviral small molecule compound, as agonists of the RLR pathway.

  • Narlaprevir

    Narlaprevir is a potent, selective, orally bioavailable NS3 protease inhibitor(Ki=6 nM; EC90=40 nM)